CytoSorbents Corporation (CTSO)

[biotech48]

This PR demonstrates the current cash flow situation. The company has forecast breakeven in 2018. Part of the loan will fund the large scale REFRESH 2 FDA TRIAL. "With our existing cash on hand, this non-dilutive financing further strengthens our balance sheet at an attractive cost of capital and provides sufficient working capital for the foreseeable future, allowing us to continue to pursue our aggressive growth strategy and clinical trial objectives as we increase product sales worldwide and move closer to operating cash flow breakeven," stated Ms. Kathleen P. Bloch, CPA, MBA, Chief Financial Officer of CytoSorbents Corporation.